CAH News & Events

Cardinal Health announced a significant expansion of its Actinium-225 production capabilities at the company's Center for Theranostics Advancement in Indianapolis, Indiana. The addition of a high-capacity production line to its Drug Master File will substantially increase Cardinal Health's supply of cGMP-compliant Ac-225 for use in investigational therapeutic drug products and future commercial manufacturing novel therapies. Since announcing routine Ac-225 production globally at scale at the end of 2024, Cardinal Health has quadrupled its weekly output. The company expects to continue increasing production capacity in 2026, supporting the rapidly growing global demand for targeted alpha therapies.

Cardinal Health (CAH) announced that its board of directors has appointed Patricia Hemingway Hall to succeed Gregory Kenny as chair of the board following Kenny's retirement, effective immediately. Kenny has served on the board since 2007 and as chairman since 2018. Hemingway Hall has served on the Cardinal Health board since 2013, including as chair of the governance and sustainability committee for nearly seven years.